logo
#

Latest news with #ASX200

ASX 200 sinks on Monday after US President Donald Trump vows to double steel tariffs, sends mixed messages on China trade war
ASX 200 sinks on Monday after US President Donald Trump vows to double steel tariffs, sends mixed messages on China trade war

Sky News AU

timean hour ago

  • Business
  • Sky News AU

ASX 200 sinks on Monday after US President Donald Trump vows to double steel tariffs, sends mixed messages on China trade war

The ASX 200 has fallen on Monday as Aussie investors react to mixed-messages about Donald Trump's trade war. The index is down about 0.1 per cent in the first 30 minutes of trading with aluminium producer Alcoa Corporation falling 3.5 per cent, Capstone Copper sliding 3.3 per cent and Clarity Pharmaceuticals shedding 3.5 per cent. The biggest mover on Monday is Australian brick maker Brickworks, up 13.5 per cent, after it revealed a $14b merger with investment firm Soul Patts. It comes as all eyes remain on Trump's tumultuous trade war as he indicated talks with Xi Jinping could start soon despite tensions mounting. The US President lashed out in a Truth Social post where he claimed China had 'totally violated its agreement' on tariffs just two weeks after striking a deal. 'I made a FAST DEAL with China in order to save them from what I thought was going to be a very bad situation,' Trump posted on Friday morning. 'Everybody was happy! That is the good news!!! The bad news is that China, perhaps not surprisingly to some, HAS TOTALLY VIOLATED ITS AGREEMENT WITH US.' Trump later told reporters he was confident the pair would meet to discuss the tense trade relations between the pair. 'They violated a big part of the agreement we made, but I'm sure that I'll speak to President Xi, and hopefully we'll work that out,' Trump said. Investors are also cautious of Trump's Saturday announcement that steel tariffs would double from 25 to 50 per cent. Resources Minister Madeleine King said the Prime Minister will talk with Trump about his decision on the sidelines of the G7 event and put forward Australia's case for an exemption. 'We are going to continue to engage and strongly advocate for the removal of these tariffs,' Ms King said on ABC Radio National on Monday. The S&P 500 finished flat, the Dow Jones rose 0.1 per cent and the Nasdaq sank 0.3 per cent on Friday. London's FTSE 250 Index jumped 0.1 per cent, Germany's DAX added 0.3 per cent and the STOXX Europe 600 Index rose 0.1 per cent on Friday. Japan's Nikkei 225 is down 1.2 per cent on Monday and South Korea's KOSPI is up 0.9 per cent.

ASX Penny Stocks To Consider In June 2025
ASX Penny Stocks To Consider In June 2025

Yahoo

time6 hours ago

  • Business
  • Yahoo

ASX Penny Stocks To Consider In June 2025

The Australian market is experiencing some turbulence, with futures indicating a slight decline for the ASX 200, largely influenced by ongoing international trade uncertainties. Despite these fluctuations, investors continue to seek opportunities in various sectors, including the often-overlooked realm of penny stocks. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer unique opportunities for growth and value when supported by solid financials. Name Share Price Market Cap Financial Health Rating Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ CTI Logistics (ASX:CLX) A$1.85 A$149.01M ★★★★☆☆ Accent Group (ASX:AX1) A$1.90 A$1.14B ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.565 A$73.83M ★★★★★★ IVE Group (ASX:IGL) A$2.55 A$393.16M ★★★★★☆ GTN (ASX:GTN) A$0.61 A$116.42M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.50 A$166.08M ★★★★★★ Regal Partners (ASX:RPL) A$2.33 A$783.26M ★★★★★★ Tasmea (ASX:TEA) A$2.99 A$699.78M ★★★★★☆ SHAPE Australia (ASX:SHA) A$3.29 A$272.21M ★★★★★★ Click here to see the full list of 1,000 stocks from our ASX Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$175.90 million. Operations: Revenue Segments: No specific revenue segments have been reported for Aroa Biosurgery Limited. Market Cap: A$175.9M Aroa Biosurgery has demonstrated notable progress, with sales reaching NZ$84.7 million for the year ending March 31, 2025, reflecting an increase from the previous year. Despite a net loss of NZ$3.81 million, this marks an improvement from prior losses. The company is debt-free and maintains a strong cash position with short-term assets surpassing liabilities significantly, ensuring a stable financial runway for over three years. Recent clinical evidence highlights the efficacy of its Endoform Natural product in treating venous leg ulcers more effectively than competitors, potentially enhancing patient outcomes and reducing costs in wound care management. Click to explore a detailed breakdown of our findings in Aroa Biosurgery's financial health report. Examine Aroa Biosurgery's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Baby Bunting Group Limited operates as a retailer of maternity and baby goods in Australia and New Zealand, with a market cap of A$233.41 million. Operations: The company generates A$496.90 million in revenue from its specialty retail segment. Market Cap: A$233.41M Baby Bunting Group's financial position is mixed, with a market cap of A$233.41 million and revenue of A$496.90 million from its specialty retail segment. The company faces challenges, such as negative earnings growth over the past year and declining profit margins, currently at 1.2%. Despite these issues, Baby Bunting maintains a satisfactory net debt to equity ratio of 8.6%, with debt well covered by operating cash flow at 177.9%. However, short-term assets do not cover long-term liabilities (A$132 million), and interest coverage by EBIT is low at 2.2x, indicating potential financial strain ahead. Jump into the full analysis health report here for a deeper understanding of Baby Bunting Group. Explore Baby Bunting Group's analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: COSOL Limited, along with its subsidiaries, offers information technology services across the Asia Pacific, North America, Europe, the Middle East, Africa, and globally with a market cap of A$142.86 million. Operations: The company generates revenue primarily from its Asia Pacific operations, contributing A$98.75 million, and North American activities, adding A$12.26 million. Market Cap: A$142.86M COSOL Limited, with a market cap of A$142.86 million, demonstrates mixed financial health. Trading at a value price-to-earnings ratio of 16x and offering high-quality earnings, it presents potential value compared to peers. However, its short-term assets (A$32.3M) do not cover long-term liabilities (A$40.7M), and net profit margins have declined from 9.5% to 8.1%. The company's debt is well covered by operating cash flow at 25%, but the dividend yield of 3.04% isn't supported by free cash flows. Recent inclusion in the S&P/ASX All Ordinaries Index highlights its growing recognition in the market. Get an in-depth perspective on COSOL's performance by reading our balance sheet health report here. Gain insights into COSOL's future direction by reviewing our growth report. Reveal the 1,000 hidden gems among our ASX Penny Stocks screener with a single click here. Ready For A Different Approach? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ARX ASX:BBN and ASX:COS. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ASX Penny Stocks To Consider In June 2025
ASX Penny Stocks To Consider In June 2025

Yahoo

time6 hours ago

  • Business
  • Yahoo

ASX Penny Stocks To Consider In June 2025

The Australian market is experiencing some turbulence, with futures indicating a slight decline for the ASX 200, largely influenced by ongoing international trade uncertainties. Despite these fluctuations, investors continue to seek opportunities in various sectors, including the often-overlooked realm of penny stocks. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer unique opportunities for growth and value when supported by solid financials. Name Share Price Market Cap Financial Health Rating Lindsay Australia (ASX:LAU) A$0.71 A$225.19M ★★★★☆☆ CTI Logistics (ASX:CLX) A$1.85 A$149.01M ★★★★☆☆ Accent Group (ASX:AX1) A$1.90 A$1.14B ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$1.565 A$73.83M ★★★★★★ IVE Group (ASX:IGL) A$2.55 A$393.16M ★★★★★☆ GTN (ASX:GTN) A$0.61 A$116.42M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$3.50 A$166.08M ★★★★★★ Regal Partners (ASX:RPL) A$2.33 A$783.26M ★★★★★★ Tasmea (ASX:TEA) A$2.99 A$699.78M ★★★★★☆ SHAPE Australia (ASX:SHA) A$3.29 A$272.21M ★★★★★★ Click here to see the full list of 1,000 stocks from our ASX Penny Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix technology in the United States and internationally, with a market cap of A$175.90 million. Operations: Revenue Segments: No specific revenue segments have been reported for Aroa Biosurgery Limited. Market Cap: A$175.9M Aroa Biosurgery has demonstrated notable progress, with sales reaching NZ$84.7 million for the year ending March 31, 2025, reflecting an increase from the previous year. Despite a net loss of NZ$3.81 million, this marks an improvement from prior losses. The company is debt-free and maintains a strong cash position with short-term assets surpassing liabilities significantly, ensuring a stable financial runway for over three years. Recent clinical evidence highlights the efficacy of its Endoform Natural product in treating venous leg ulcers more effectively than competitors, potentially enhancing patient outcomes and reducing costs in wound care management. Click to explore a detailed breakdown of our findings in Aroa Biosurgery's financial health report. Examine Aroa Biosurgery's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Baby Bunting Group Limited operates as a retailer of maternity and baby goods in Australia and New Zealand, with a market cap of A$233.41 million. Operations: The company generates A$496.90 million in revenue from its specialty retail segment. Market Cap: A$233.41M Baby Bunting Group's financial position is mixed, with a market cap of A$233.41 million and revenue of A$496.90 million from its specialty retail segment. The company faces challenges, such as negative earnings growth over the past year and declining profit margins, currently at 1.2%. Despite these issues, Baby Bunting maintains a satisfactory net debt to equity ratio of 8.6%, with debt well covered by operating cash flow at 177.9%. However, short-term assets do not cover long-term liabilities (A$132 million), and interest coverage by EBIT is low at 2.2x, indicating potential financial strain ahead. Jump into the full analysis health report here for a deeper understanding of Baby Bunting Group. Explore Baby Bunting Group's analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: COSOL Limited, along with its subsidiaries, offers information technology services across the Asia Pacific, North America, Europe, the Middle East, Africa, and globally with a market cap of A$142.86 million. Operations: The company generates revenue primarily from its Asia Pacific operations, contributing A$98.75 million, and North American activities, adding A$12.26 million. Market Cap: A$142.86M COSOL Limited, with a market cap of A$142.86 million, demonstrates mixed financial health. Trading at a value price-to-earnings ratio of 16x and offering high-quality earnings, it presents potential value compared to peers. However, its short-term assets (A$32.3M) do not cover long-term liabilities (A$40.7M), and net profit margins have declined from 9.5% to 8.1%. The company's debt is well covered by operating cash flow at 25%, but the dividend yield of 3.04% isn't supported by free cash flows. Recent inclusion in the S&P/ASX All Ordinaries Index highlights its growing recognition in the market. Get an in-depth perspective on COSOL's performance by reading our balance sheet health report here. Gain insights into COSOL's future direction by reviewing our growth report. Reveal the 1,000 hidden gems among our ASX Penny Stocks screener with a single click here. Ready For A Different Approach? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:ARX ASX:BBN and ASX:COS. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store